Search

EHA-SWG Scientific Meeting on Red Cell and Iron Metabolism Defects: From Basic Science to Clinical Case Application

Dates: October 12-14, 2023
Location: Budapest, Hungary
Chairs: A Taher & A Iolascon
Collaborating SWG: EHA Specialized Working Group on Red Cells and Iron

Registration is closed

RegistrationRegistration is closed. Visit this page for more information.

EHA-SWG Scientific Meeting on From aging hematopoietic stem cells to age-related diseases: opportunities for intervention Page

Dates: November 13-15, 2025
Location: Barcelona, Spain
Chairs: M Essers, E Laurenti, S Valetta, K Kirschner
Collaborating SWG: EHA Specialized Working Group (SWG) on Stem Cells and SWG on Aging

Registration will be open soon

Join leading experts in hematopoietic stem cell (HSC) biology and aging, and…

The root of evil: pre-leukemic clones that survive chemotherapy are linked to a higher risk of leukemia recurrence

Jun 10 2016 Posted in Press releases

Acute myeloid leukemia (AML) is an aggressive form of blood cancer. Treatment with intensive chemotherapy often leads to a period of freedom from overt disease called a remission. However, recurrence of the disease is common.

Publications

Overall Survival With Daratumumab, Bortezomib, and Dexamethasone in Previously Treated Multiple Myeloma (CASTOR): A Randomized, Open-Label, Phase III Trial
P. Sonneveld, A. Chanan-Khan, K. Weisel, A. K. Nooka, T. Masszi, M. Beksac, I. Spicka, V. Hungria, M. Munder, M.

Compliance and reports

EHA is a non-governmental and not-for-profit membership organization that is guided by its mission to promote excellence in patient care, research, and education in hematology.

Adding elotuzumab to standard treatment for multiple myeloma significantly reduced the risk of disease progression, with benefits sustained at two years

Jun 12 2015

ELOQUENT-2, which evaluated elotuzumab in combination with lenalidomide and dexamethasone, is the first Phase III study to demonstrate the benefit of directly activating the immune system in the treatment of patients with relapsed or refractory multiple myeloma.

EHA-LSHBT Virtual Hematology Updates

EHA and the Lebanese Society of Hematology and Blood Transfusion (LSHBT) have initiated a webinar course dedicated to practitioners who manage patients with benign and hematologic malignancies.